Medline Forecast, price target & analysts
Medline Target price 2026 - Analyst rating & recommendation
Medline Classifications & Recommendation
Medline Price Target
| Target Price | $45.90 |
| Price | $34.70 |
| Potential |
32.28%
register free of charge
|
| Number of Estimates | 29 |
|
29 Analysts have issued a price target Medline 2027 .
The average Medline target price is $45.90.
This is
32.28%
register free of charge
$57.75
66.43%
register free of charge
$34.34
1.04%
register free of charge
|
|
| A rating was issued by 34 analysts: 27 Analysts recommend Medline to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Medline stock has an average upside potential 2027 of
32.28%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 28.43 | 31.86 |
| 11.47% | 12.04% | |
| EBITDA Margin | 10.31% | 10.85% |
| 11.61% | 5.21% | |
| Net Margin | 4.08% | 6.41% |
| 13.35% | 57.25% |
29 Analysts have issued a sales forecast Medline 2026 . The average Medline sales estimate is
This results in the following potential growth metrics:
29 Analysts have issued an Medline EBITDA forecast 2026. The average Medline EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
29 Medline Analysts have issued a net profit forecast 2026. The average Medline net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.43 | 1.55 |
| 4.67% | 8.39% | |
| P/E | 22.34 | |
| EV/Sales | 1.74 |
29 Analysts have issued a Medline forecast for earnings per share. The average Medline EPS is
This results in the following potential growth metrics and future valuations:
Current Medline Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BTIG |
Locked
➜
Locked
|
Locked | Aug 27 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 11 2026 |
| Tigress Financial |
Locked
➜
Locked
|
Locked | Aug 11 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BTIG:
Locked
➜
Locked
|
Aug 27 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 11 2026 |
|
Locked
Tigress Financial:
Locked
➜
Locked
|
Aug 11 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 06 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
